Cardiac sympathetic denervation from the early stage of Parkinson's disease: Clinical and experimental studies with radiolabeled MIBG

Journal of Nuclear Medicine

Volumn 41, Issue 1, 2000, Pages 71-77

  Takatsu, Hisato ^a   Nishida, Hiroshi ^b   Matsuo, Hitoshi ^b   Watanabe, Sachiro ^b   Nagashima, Kenshi ^b   Wada, Hisayasu ^b   Noda, Toshiyuki ^b   Nishigaki, Kazuhiko ^b   Fujiwara, Hisayoshi ^b  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

123I MIBG; Autonomic disorder; Orthostatic hypotension; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HEART DENERVATION; HEART SCINTISCANNING; HUMAN; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; POSTGANGLIONIC NERVE; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3-IODOBENZYLGUANIDINE; AGED; ANIMALS; AUTONOMIC NERVOUS SYSTEM DISEASES; CASE-CONTROL STUDIES; DOPAMINE AGENTS; FEMALE; HEART; HUMANS; IODINE RADIOISOTOPES; MALE; MICE; MICE, INBRED C57BL; PARKINSON DISEASE; RADIOPHARMACEUTICALS; TIME FACTORS;

EID: 0033955289     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Beal MF, Fink JS, Martin JB. Parkinson's disease and other extrapyramidal disorders. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principles of Internal Medicine. 13th ed. New York, NY: McGraw-Hill; 1994:2275-2280.
2. Sudarsky LR. Parkinsonism and movement disorders. In: Sudarsky L, ed. Pathophysiology of the Nervous System. Boston, MA: Little, Brown; 1990:1949-1954.
3. van Dijk JG, Haan J, Zwinderman K, Kremer B, van Hilten BJ, Roos RAC. Autonomic nervous system dysfunction in Parkinson's disease: relationship with age, medication, duration, and severity. J Neurol Neurosurg Psychiatry. 1993;37: 99-102.
4. Koike Y, Takahashi A. Autonomic dysfunction in Parkinson's disease. Eur Neurol. 1997;38(suppl 2):8-12.
5. Loew F, Gauthey L, Koerffy A, et al. Postprandial hypotension and orthostatic blood pressure responses in elderly Parkinson's disease patients. J Hypertens. 1995;13:1291-1297.
6. Brevetti G, Bonaduce D, Breglio R, et al. Parkinson's disease and hypotension: 24-hour blood pressure recording in ambulant patients. Clin Cardiol. 1990;13:474-478.
7. Senard JM, Chamontin B, Rascol A, Montastruc JL. Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension. Clin Auton Res. 1992,2:99-104.
8. Hakamäki T, Rajala T, Lehtonen. Ambulatory 24-hour blood pressure recordings in patients with Parkinson's disease with or without fludrocortisone. Int J Clin Pharmacol Ther. 1998;36:367-370.
9. Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jacques S. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med. 1987;28:1620-1624.
10. Stanton MS, Tuli MM, Radke NL, et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine. J Am Coll Cardiol. 1988;14:1519-1526.
11. Takatsu H, Uno Y, Fujiwara H. Modulation of left ventricular iodine-125-MIBG accumulation in cardiomyopathic Syrian hamsters using renin-angiotensin system. J Nucl Med. 1995;36:1055-1061.
12. Takatsu H, Scheffel U, Fujiwara H. Sympathetic tone assessed by washout of iodine-125-labeled metaiodobenzylguanidine from the murine left ventricle: influence of immobilization stress and inhibition of the renin-angiotensin system. J Nucl Cardiol. 1995;2:507-512.
13. 131I]metaiodobenzylguanidine after ischemia and reperfusion in anesthetized dogs. J Nucl Cardiol. 1997;4:33-41.
14. Sisson JC, Shapiro B, Myers L, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med. 1987;28:1625-1636.
15. 123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst. 1994;49:81-84.
16. 123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst. 1995;53:230-234.
17. 123I-metaiodobenzyl guanidine in Parkinson's disease. Nucl Med Commun. 1998;19: 137-142.
18. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 metaiodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998;155:60-67.
19. Nakata T, Shimamoto K, Yonekura S, et al. Cardiac sympathetic denervation in transthyretin-related familial amyloidotic polyneuropathy: detection with iodine-123-MIBG. J Nucl Med. 1995;36:1040-1042.
20. Tanaka M, Hongo M, Kinoshita O, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of cardiac sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol. 1997;29:168-174.
21. Hoehn MM, Yahr MD. Parkinsonism: progression and mortality. Neurology. 1976;17:427-442.
22. Consensus statement: the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. J Auton Nerv Syst. 1996;58:123-124.
23. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992;13: 513-521.
24. Merlet P, Valette H, Dubois-Rande J, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-477.
25. Tsuchimori S, Tamaki N, Tadamura E, et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med. 1995;36:969-974.
26. Kario K, Matsuo T, Kobayashi H, et al. Relation between nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensives; advanced silent cerebrovascular damage in extreme-dippers. Hypertension. 1996;27:130-135.
27. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in human due to a product of meperidine-analog synthesis. Science. 1982;219:979-980.
28. Sonsalla PK, Heikkila RE. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxity in mice. Eur J Pharmacol. 1986;129: 339-345.
29. Sundström E, Strömberg I, Tsutsumi T, Olson L, Jonsson G. Studies on the effect of 1-methy-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP) on central catecholamine neurons in C57 BL/6 mice; comparison with three other strains of mice. Brain Res. 1987;405:26-38.
30. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res. 1990;26:428-435.
31. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol. 1992;32:804-812.
32. 123I]iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol Scand. 1998;97:307-314.
33. Kario K, Motai K, Mitsuhashi T, et al. Autonomic nervous system dysfunction in elderly hypertensive patients with abnormal diurnal blood pressure variation: relation to silent cerebrovascular disease. Hypertension. 1997;30:1504-1510.
34. Edwards RH. Neural degeneration and the transport of neurotransmitters. Ann Neurol. 1993;34:638-645.
35. Cohen G. Monoamine oxidase and oxidative stress at dopaminergic synapses. J Neural Transm. 1990;32(suppl):229-238.
36. Durrieu G, Senard JM, Tran MA, Rascol A, Montastruc JL. Effects of levodopa and bromocriptine on blood pressure and plasma catecholamines in Parkinsonians. Clin Neuropharmacol. 1991;14:84-90.